ZIM Laboratories has received Marketing Authorization (MA) from Therapeutic Goods Administration (TGA), Australia for its Central Nervous System (CNS) product ‘Rizatriptan Benzoate Orally Disintegrating Films’ through its Australian Subsidiary, ZIMTAS.
This approval marks ZIM’s first Marketing Authorization in Australia and represents an important milestone in the Company’s strategy to expand its presence in regulated markets through innovative drug delivery technologies.
Rizatriptan, a selective 5-HT?B/?D receptor agonist, is indicated for the acute treatment of migraine attacks, with or without aura, in adults. The orally disintegrating film (ODF) formulation developed using ZIM’s proprietary technology platform offers a patient-friendly alternative that enables rapid onset of action without the need for water, making it especially convenient for patients experiencing nausea or vomiting during migraine episodes.
This milestone reflects ZIM’s continued focus on differentiated, technology-driven generics designed to improve treatment adherence and patient experience.
ZIM Laboratories manufactures, formulates, and distributes drug delivery systems to develop generic pharmaceutical products.
